|
Mar 13
|
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
|
|
Mar 7
|
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
|
|
Mar 7
|
UPDATE 2-US FDA approves expanded use of BeiGene's blood cancer drug
|
|
Mar 7
|
Q4 2023 Zymeworks Inc Earnings Call
|
|
Mar 6
|
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
|
|
Feb 2
|
10 Blue-Chip Stocks At 52-Week Lows
|
|
Jan 31
|
Adults living with chronic lymphocytic leukemia (CLL) in Ontario and Quebec now have access, through public reimbursement, to BRUKINSA® (zanubrutinib)
|
|
Jan 1
|
A Look At The Intrinsic Value Of BeiGene, Ltd. (NASDAQ:BGNE)
|
|
Dec 28
|
12 High Growth International Stocks to Buy
|
|
Dec 22
|
FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)
|
|
Dec 21
|
3 Cancer-Focused Biotechs That Appear Promising Bets for 2024
|
|
Dec 21
|
BeiGene to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 19
|
13 Most Promising Healthcare Stocks According to Analysts
|
|
Dec 19
|
5 Nasdaq Composite Laggards Likely to Gather Pace in 2024
|
|
Dec 4
|
Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca
|
|
Nov 30
|
Wall Street Analysts Think BeiGene, Ltd. (BGNE) Could Surge 44.28%: Read This Before Placing a Bet
|
|
Nov 29
|
BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023
|
|
Nov 28
|
BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023
|
|
Jul 21
|
BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC
|